Elevated triglycerides and reduced high-density lipoprotein cholesterol are independently associated with the onset of advanced chronic kidney disease: a cohort study of 911,360 individuals from the United Kingdom

Table 2 Association between the quarters of baseline lipids levels with hazard of CKD stages 4–5

Lipid quarter	No. of events	Total	Hazard ratio (95% confidence interval)
Lipid quarter	No. of events	Total	Model 1	Model 2
TC
Q1	3489	227,711	1 (Ref)	1 (Ref)
Q2	2713	222,006	0.74 [0.71–0.78]	1.01 [0.95–1.09]
Q3	2673	230,520	0.64 [0.61–0.67]	0.98 [0.90–1.05]
Q4	2950	231,123	0.62 [0.59–0.65]	0.90 [0.83–0.97]
TG
Q1	837	161,250	1 (Ref)	1 (Ref)
Q2	1552	164,514	1.35 [1.24–1.46]	1.04 [0.93–1.17]
Q3	2325	175,422	1.77 [1.63–1.91]	1.08 [0.97–1.21]
Q4	2953	159,952	2.69 [2.49–2.90]	1.28 [1.15–1.43]
*LDL-C*
Q1	1607	136,004	1 (Ref)	1 (Ref)
Q2	9,66	117,132	0.69 [0.63–0.74]	0.92 [0.83–1.03]
Q3	1010	128,509	0.60 [0.55–0.65]	0.91 [0.81–1.03]
Q4	1152	124,492	0.61 [0.57–0.66]	0.95 [0.85–1.07]
*HDL-C*
Q1	2366	165,744	2.61 [2.42–2.80]	1.27 [1.14–1.41]
Q2	2154	196,406	1.69 [1.57–1.82]	1.10 [1.00–1.22]
Q3	1105	129,916	1.21 [1.11–1.31]	0.99 [0.88–1.11]
Q4	1210	158,641	1 (Ref)	1 (Ref)

Model 1: adjusted for sex and age; Model 2: adjusted for model 1 plus smoking status, IMD tenth, SBP, BMI, eGFR, prior diabetes mellitus, prior CVD, antihypertensive medication, insulin, and statin use. CKD stages 4–5 were determined if there were at least two eGFR measurements < 30 mL/min/1.73m², separated by at least three months, with no eGFR result ≥30 mL/min/1.73m² in the intervening period

ISSN: 1471-2369